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ABSTRACT Previous reports link differential DNA methylation (DNAme) to environmental exposures
that are associated with lung function. Direct evidence on lung function DNAme is, however, limited. We
undertook an agnostic epigenome-wide association study (EWAS) on pre-bronchodilation lung function
and its change in adults.
In a discovery–replication EWAS design, DNAme in blood and spirometry were measured twice,
6–15 years apart, in the same participants of three adult population-based discovery cohorts (n=2043).
Associated DNAme markers (p<5×10−7) were tested in seven replication cohorts (adult: n=3327;
childhood: n=420). Technical bias-adjusted residuals of a regression of the normalised absolute β-values
on control probe-derived principle components were regressed on level and change of forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and their ratio (FEV1/FVC) in the covariate-adjusted
discovery EWAS. Inverse-variance-weighted meta-analyses were performed on results from discovery and
replication samples in all participants and never-smokers.
EWAS signals were enriched for smoking-related DNAme. We replicated 57 lung function DNAme markers
in adult, but not childhood samples, all previously associated with smoking. Markers not previously associated
with smoking failed replication. cg05575921 (AHRR (aryl hydrocarbon receptor repressor)) showed the
statistically most significant association with cross-sectional lung function (FEV1/FVC: pdiscovery=3.96×10−21
and pcombined=7.22×10−50). A score combining 10 DNAme markers previously reported to mediate the
effect of smoking on lung function was associated with lung function (FEV1/FVC: p=2.65×10−20).
Our results reveal that lung function-associated methylation signals in adults are predominantly smoking
related, and possibly of clinical utility in identifying poor lung function and accelerated decline. Larger studies
with more repeat time-points are needed to identify lung function DNAme in never-smokers and in children.
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Introduction
Lung function has an estimated heritability of between 30% and 70% [1]. The variance in phenotype
remains incompletely explained by genetic variation, but the impact of environmental exposure on
respiratory health and lung function over the life course is well recognised. In particular, pro-inflammatory
and oxidative inhalants such as cigarette and environmental tobacco smoke, air pollution, and
occupational exposures are important contributors to the increased risk of respiratory symptoms,
accelerated lung function decline in adults and poor lung growth in children. DNA methylation (DNAme)
has been associated with a wide variety of traits and chronic diseases.
A large body of evidence including results from epigenome-wide association studies (EWASs) shows
differentially methylated CpG (5′-cytosine-phosphate-guanine-3′ dinucleotide) sites throughout the
genome in response to environmental exposures, in particular cigarette smoking [2–4]. In contrast, reports
of DNAme associated with respiratory diseases and lung function show inconsistent findings [5, 6]. Most
recently, however, independent reports pointed to the consistent association of DNAme in the AHRR
gene, cg05575921, with lung function in adults [4, 6, 7].
The current study aimed at agnostically identifying lung function-specific DNAme signals. We undertook
a covariate-adjusted EWAS using questionnaire data, spirometry and peripheral blood samples collected in
the same participants (discovery cohorts: ECRHS (European Community Respiratory Health Study),
NFBC1966 (Northern Finland Birth Cohort 1966) and SAPALDIA (Swiss Study on Air Pollution Heart
and Lung Disease in Adults); cohort description in supplementary material) at two time-points 6–15 years
apart. EWAS analyses were performed on lung function parameters of forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC) and their ratio (FEV1/FVC). The analyses focused on cross-sectional
associations at different time-points and on identifying DNAme markers predicting change in lung
function. We tested discovery-identified CpGs (p<5×10−7 for at least one lung function parameter) for
replication in adult samples from five adult cohorts (LBC1936 (Lothian Birth Cohort 1936, adult inception
birth cohort), KORA (Cooperative Health Research in the Augsburg Region Study), LifeLines (LifeLines
cohort study), NSPHS (North Sweden Population Health Study) and FTC (Finnish Twin Cohort study))
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and in childhood samples from two birth cohorts (ALSPAC (Avon Longitudinal Study of Parents and
Children) and IOWBC (Isle of Wight Birth Cohort)).
Methods
Study design and participants
The discovery sample (n=2043) comprised three population-based cohort studies, part of the Aging Lungs
in European Cohorts (ALEC) project. ECRHS (n=470) and SAPALDIA (n=962) are adult cohorts
designed to investigate respiratory health. NFBC1966 (n=611) is a birth cohort with follow-up to adult
age. The replication sample consisted of five adult cohorts (KORA (n=628), LifeLines (n=1622), NSPHS
(n=535), LBC1936 (n=449) and FTC (n=93)) and two childhood birth cohorts (ALSPAC (n=258) and
IOWBC (n=162)). Replication data from two time-points were available only for KORA and LBC1936
(adult) and ALSPAC and IOWBC (childhood). For cohort details and contribution to analysis, refer to the
supplementary material and supplementary figure S1.
All cohorts comply with the Declaration of Helsinki, and ethical approval was obtained from the
respective national and regional ethical review committees.
Procedures
In the discovery cohorts, DNAme measurements using Infinium technology (Illumina, San Diego, CA,
USA) were obtained from peripheral blood samples collected at two consecutive follow-up surveys several
years apart. The Infinium 450K BeadChip was used for samples of 984 SAPALDIA participants from both
time-points and of 732 NFBC1966 participants collected at time-point 1. The Infinium EPIC BeadChip
was used for samples of 509 ECRHS participants from both time-points and of 716 NFBC1966
participants collected at time-point 2. For cohort-specific EWAS analyses, we used all autosomal markers
available for each time-point and cohort-specific EWAS marker results were meta-analysed without
restriction to markers common to both arrays. DNAme data used for replication were restricted to
discovery-identified (sentinel) CpGs and analysed on various arrays.
Epidemiological data, including covariate information at the subject level, were collected by interview-
assisted questionnaires and objective measures. Pre-bronchodilation spirometric data were obtained by
performing American Thoracic Society/European Respiratory Society-compliant spirometry (supplementary
material).
Statistical analyses
Epigenome-wide methylation data were analysed in R version 3.4.3 (R Foundation for Statistical
Computing, Vienna, Austria). Differential blood cell count was estimated using a reference dataset and the
R package minfi [8, 9]. DNAme used as predictors in the statistical models for the adult cohorts were
obtained by deriving residuals from linear regression of the normalised absolute DNAme (β-values) on the
Illumina control probe-derived 30 first principal components to correct for correlation structures within
the data, including technical bias. Thus, effect sizes reported here of the association are not comparable to
effect sizes reported elsewhere using normalised β-values as predictor. In the childhood data, batch effect
was corrected at the analysis level by regressing the DNAme values against the technical covariates.
Epigenome-wide covariate-adjusted linear regression was performed to assess the association of single CpG
markers with FEV1 (L), FVC (L), their ratio (FEV1/FVC) and their change during follow-up. This multilevel
EWAS design tested different models in all participants and never-smoking participants (figure 1). First,
cross-sectional EWASs were examined separately at time-point 1 (EWAS1) and time-point 2 (EWAS2) to
assess the consistency of the association over follow-up time. Second, the association of DNAme at the first
time-point (DNAme1) with change in lung function during follow-up was assessed (prediction EWAS
(EWASpredict)). Covariate-adjusted mixed linear regressions with a random intercept on the subject were
undertaken using data from both time-points (repeat cross-sectional analysis (EWASrepeat)).
All associations were adjusted for a set of a priori selected covariates known to influence respiratory
outcomes from previous research conducted by SAPALDIA and ECRHS. The covariate-adjusted model
(Mbase) included age, age squared, height, squared deviation from the mean of height, sex and interaction
terms of sex with four covariates (age, age squared, height and squared deviation of height), education,
body mass index, spirometer type, study centre as well as estimated cell composition (CD8 cells, CD4 cells,
natural killer cells, B-cells, monocytes, eosinophils and neutrophils). Analyses in all participants were run
without (Mbase) and with additional smoking adjustment including smoking status and pack-years
(Msmok). Mbase covariate adjustment was applied in never-smokers. Prediction associations of DNAme1
were additionally adjusted for lung function at time-point 1. The same covariate adjustment was applied in
adult replication analyses, whereas childhood covariates did not include squared terms.
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Cohort-specific EWAS results were summarised by inverse-variance-weighted meta-analyses using
METAL [10]. Meta-analysis results were not controlled for genomic inflation after confirming its negligible
influence. Epigenome-wide significance level was set to p<1×10−7 (Bonferroni correction, 450000 tests).
The selection criteria for replication of sentinel CpGs was less stringent (p<5×10−7). Successful replication
was defined as a p-value below the outcome-specific Bonferroni correction threshold.
Replicated CpGs were characterised by enrichment, pathway and functional analyses, and additional post hoc
analyses were performed (details in supplementary material). 1) A two-sample Mendelian randomisation
analysis based on publicly available data was applied to investigate the causality of replicated CpG
associations. 2) A replication of a recently published mediation analysis [4] evidencing 10 smoking-related
CpGs mediating the effect of smoking on lung function was undertaken in one discovery cohort
(SAPALDIA). 3) To assess the combined effects of smoking-related CpGs on lung function in three
discovery cohorts, we built two different DNAme smoking indices based on CpGs: a) predicting lung
function effects of smoking [4] and b) located in genome-wide association study (GWAS)-identified
lung function genes [2]. These smoking indices were tested for association with lung function in
covariate-adjusted linear regression analyses, in all participants and in subgroups stratified by smoking status.
Data availability statement
Statistical codes and full discovery/replication EWAS effect estimates (meta-analysed and cohort-specific)
are made publically available with no end date on the public repository DRYAD (http://datadryad.org/) at
the time of publication. Access restrictions apply to the individual methylome data underlying the analysis.
Contact details for data requests to the contributing cohorts can be found in the supplementary material.
Results
Differences in the cohorts’ age structure and smoking habits are shown in tables 1 and 2. Mean age was
highest for LBC1936 (69.9 years) and youngest for FTC (30.4 years). Self-report of current smoking status
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FIGURE 1 Flow of the multilevel discovery design of the epigenome-wide association study (EWAS) on lung
function parameters: forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC.
DNAme1: DNA methylation at time-point 1; DNAme2: DNA methylation at time-point 2. #: base model (Mbase)
EWAS was covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex
and interaction terms of age, age squared, height and squared deviation of height with sex, education (low,
medium and high), body mass index, spirometer type, study centre, and cell composition. ¶: smoking model
EWAS (Msmok) additionally adjusted for smoking covariates: history of smoking intensity as pack-years
smoked up to the time-point of data collection for regressions and for smoking status (current smoker,
ex-smoker and never-smoker). EWAS longitudinally predicting the change in lung function (EWASpredict) was
additionally adjusted for lung function at time-point 1.
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was lowest in LBC1936 (5.8%) and highest in LifeLines (43.5% due to oversampling of current smokers for
the DNAme-typed subset).
Across all discovery EWAS meta-analyses, we identified 111 CpG markers for replication (p<5×10−7: 74
for FEV1, 16 for FVC and 47 for FEV1/FVC) (supplementary tables S1 and S2). We present here the
results for FEV1/FVC (for FEV1 and FVC, refer to the supplementary material).
Cross-sectional associations without smoking adjustment
In the study-specific and meta-analysed discovery EWAS, the number of lung function-associated DNAme
increased from the first to second cross-sectional time-point in the same participants, despite age adjustment
(figure 2a and b). We therefore meta-analysed cross-sectional discovery and replication results from the
older participants’ age time-point available. We observed 29 cross-sectional CpG associations with FEV1/
FVC. 27 of them replicated formally (Bonferroni correction, p<0.0011; 47 tests on FEV1/FVC) (table 3 and
supplementary table S3). All replicated CpG lung function associations were exclusively DNAme previously
associated with smoking [2]. Successful replication was observed for cg05575921 (AHRR), showing the
strongest signal for FEV1 and FEV1/FVC (FEV1/FVC: p-value combining discovery and replication cohorts
(pcombined)=7.22×10−50) among all identified lung function DNAme markers. Methylation at this CpG,
previously shown to be hypomethylated with increased smoking, showed positive cross-sectional lung
function association. The top 10 CpGs associated with FEV1/FVC (table 3) were located in six loci:
cg03636183 (F2RL3), cg21566642, cg01940273 and cg03329539 (vicinity of ALPPL2), cg05575921 and
cg21161138 (AHRR), cg23771366 and cg11660018 (PRSS23), cg21611682 (LRP5), and cg15342087 (IER3).
The same CpGs, along with cg19572487 (RARA), were also among the top 11 markers cross-sectionally
associated with FEV1. Formal replication of cross-sectional associations with FEV1 was observed for 44
CpGs and with FVC for three CpGs (supplementary tables S4 and S5). Similar results were found for repeat
cross-sectional analyses (EWASrepeat) (supplementary table S6 and supplementary figure S3).
TABLE 1 Characteristics of discovery cohorts
SAPALDIA 2
time-point 1
SAPALDIA 3
time-point 2
ECRHS II
time-point 1
ECRHS III
time-point 2
NFBC1966
(age 31 years)
time-point 1
NFBC1966
(age 46 years)
time-point 2
Subjects n 962 962 470 470 611 611
Female 53.5 53.5 56 56 55.3 55.3
Age years 50.5±11.3 58.8±11.3 43.6±6.8 54.5±6.8 31.0±0.3 46.3±0.4
Height cm 169.4±9.2 168.7±9.4 170.0±9.2 169.2±9.3 171±8.8 171±8.9
Weight kg 74.2±14.7 75.5±15.4 72.6±14.6 76.2±15.5 71.3±13.6 78.7±16.3
Body mass index kg·m−2 25.8±4.4 26.5±4.6 25.0±4.0 26.5±4.4 24.2±3.7 26.7±4.8
Smoking status
Never-smoker# 41.7 41.1 43.2 41.7 54.5 54.5
Ex-smoker 30.0 37.0 31.1 40.4 21.3 30.2
Current smoker 28.3 21.9 25.7 17.9 24.1 15.3
Pack-years 20.4±20.2 22.6±22.1 16.6±16.9 20.0±21.3 7.7±5.9 11.0±9.6
Education¶
Low 5.4 5.4 11.5 11.5 0.7 0.7
Intermediate 65.7 65.7 29.2 29.2 55.9 55.9
High 28.9 28.9 59.3 59.3 43.3 43.3
FVC L+ 4.4±1.0 4.1±1.1 4.3±1.0 3.9±1.0 4.8±1.0 4.5±0.9
FEV1 L+ 3.3±0.8 3.0±0.8 3.4±0.7 3.0±0.8 4.0±0.8 3.5±0.7
FEV1/FVC+ 0.75±0.07 0.73±0.08 0.78±0.06 0.75±0.06 0.83±0.06 0.77±0.06
Airflow obstruction
FEV1/FVC <0.7+ 20.4 29.5 8.9 16.2 1.8 10.8
FEV1/FVC <LLN+,§ 12.9 14.1 8.7 10.4 3.3 9.5
Doctor-diagnosed asthma 13.8 16.5 14.3 16.8 10.7 15.8
Respiratory medication (% missing values) 22.2 (0.8) 23.7 (0.3) 13.4 14.2 NA NA
Data are presented as % or mean±SD, unless otherwise stated; percentages may not total 100% due to rounding. FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal; NA: not assessed. #: self-reported lifetime nonsmoking. ¶: the categorical
variable “education” is defined differently in cohorts (in SAPALDIA low corresponds to primary education; intermediate to secondary, middle or
vocational school and high to technical college or university; in ECRHS and NFBC1966 information of age reached at end of studies is used to
define low as ⩽16 years, intermediate as 17–19 years and high as ⩾20 years). +: values derived from pre-bronchodilation spirometry (lung
function values corrected for spirometer device change in SAPALDIA at time-point 2). §: LLN values estimated using Global Lung Initiative 2012
reference equations [11].
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Cross-sectional smoking-adjusted associations
The smoking-adjusted EWAS (Msmok) resulted in fewer genome-wide significant results (figure 2c and d).
Yet, despite adjustment for self-report of smoking history, the top five CpGs were known smoking-related
CpGs. DNAme at cg05575921 (AHRR) remained the top cross-sectional association signal for FEV1/FVC
(pcombined=2.21×10−11) (supplementary table S7).
Predictive associations without smoking adjustment
The prediction EWAS results (table 4 and figure 3) revealed that DNAme at time-point 1 (DNAme1) at
six of nine sentinel CpGs (p<5×10−7) associated with change in FEV1/FVC was replicated (cg05575921
and cg21161138 (AHRR), cg21566642, cg01940273 and cg03329539 (vicinity of ALPPL2), and cg03636183
(F2RL3)). These six replicated CpGs were smoking-related markers. They were also associated with
cross-sectional FEV1/FVC and four of them also with predicting change in FEV1 (AHRR (cg05575921),
ALPPL2 (cg05951221 and cg01940273) and F2RL3 (cg03636183)) (supplementary table S8).
Associations in never-smokers
The agnostic discovery EWAS (Mbase) in never-smokers, similar to the entire sample, showed more
statistically significant associations at time-point 2 (older age). Eight CpGs were cross-sectionally
associated with FEV1/FVC in never-smokers (p<5×10−7), but none replicated (table 5 and supplementary
figure S5). The CpG cg14366110 (FIBCD1) showed predictive association of DNAme1 with change in
FEV1/FVC (pdiscovery=4.2×10−9, pcombined=3.6×10−9) in never-smokers, but it did not replicate in KORA
and LBC1936 (preplication=0.439; replication cohorts with lung function at two time-points). The direction
of effect, however, was consistent (table 6; see supplementary table S9 for cross-sectional associations and
supplementary table S10 for prediction associations) in discovery and replication cohorts.
Characterisation of replicated CpGs
None of the not-smoking-related discovery-identified sentinel CpGs (n=25) were confirmed by replication.
In contrast, 78% of the sentinel CpGs (n=86) had previously been identified as smoking related, and 57 of
TABLE 2 Characteristics of adult replication cohorts
KORA
time-point 1
KORA
time-point 2
LBC1936
time-point 1
LBC1936
time-point 2
LifeLines
time-point 1
NSPHS
time-point 1
FTC
time-point 1
Subjects n 628 628 449 449 1622 535 93
Female 53.2 53.2 46.8 46.8 42.8 53.1 47.3
Age years 53.6±4.5 60.1±4.5 69.6±0.9 76.3±0.7 46.7±10.8 55.1±16.0 30.4±3.8
Height cm 169.5±9.3 168.7±9.4 167.2±8.8 166.1±8.8 176.9±9.1 163.8±9.8 173.0±10.5
Weight kg 79.0±16.7 79.9±17.3 77.2±14.6 76.5±14.8 82.1±14.7 74.0±15.2 82.0±18.8
Body mass index kg·m−2 27.4±4.7 28.0±5.1 27.5±4.3 27.7±4.6 26.2±3.9 27.5±4.7 27.3±5.4
Smoking status
Never-smoker# 38.2 38.2 52.3 52.3 56.6 83.2 53.8
Ex-smoker 43.8 45.5 40.8 41.9 0ƒ NA## 26.9
Current smoker 18.0 16.2 6.9 5.8 43.5 16.5 19.4
Pack-years 12.8±19.3 13.5±20.2 13.9±24.0 14.1±24.6 21.0±11.7 8.1±21.6 NA
Education¶
Low 47.6 47.6 49.7 49.7 23.1 NA 1.1
Intermediate 26.4 26.4 32.3 32.3 40.8 NA 38.6
High 26.0 26.0 18.0 18.0 35.4 NA 60.2
FVC L+ 4.3±1.0 3.9±1.0 3.2±0.9 2.8±0.9 4.7±1.1 3.4±1.1 4.8±1.1
FEV1 L+ 3.3±0.8 3.0±0.7 2.5±0.7 2.1±0.7 3.5±0.9 2.8±0.9 3.9±0.9
FEV1/FVC+ 0.78±0.06 0.75±0.07 0.79±0.09 0.76±0.12 0.73±0.09 0.83±0.09 0.81±0.07
Airflow obstruction
FEV1/FVC <0.7+ 8.1 20.1 15.4 26.3 38.4 8.8 5.0
FEV1/FVC <LLN+,§ 5.0 9.6 7.6 14.9 27.5 4.3 11.3
Doctor-diagnosed asthma 7.2 8.6 4.5 7.1 9.9 14.2 0
Respiratory medication 3.3 4.9 6.7 11.8 8.0 7.7 0
Data are presented as % or mean±SD, unless otherwise stated; percentages may not total 100% due to rounding. FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal; NA: not assessed. #: self-reported lifetime nonsmoking. ¶: the categorical
variable “education” is defined differently in different cohorts. +: values derived from pre-bronchodilation spirometry. §: LLN values estimated
using Global Lung Initiative 2012 reference equations [11]. ƒ: LifeLines: nonrandom selection of samples for DNA methylation typing (current
smokers versus never-smokers). ##: NSPHS: information obtained on current smoking status (yes/no).
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these (mapping to 43 loci) formally replicated across all models and lung function outcomes tested
(supplementary table S11). They were used jointly for functional annotation and pathway analyses
(supplementary tables S12–S16). Briefly, these 57 lung function-associated CpGs displayed enrichment for
transcription factors, such as RELA (false discovery rate-adjusted p-value (pFDR)=0.002) and EP300
(pFDR=0.004), and suggestive enrichment (pFDR<0.1) for the chromatin state model of flanking active
transcription start sites, of transcription at gene 5′ and 3′, and of enhancers. No significant pathways were
revealed using Ingenuity Pathway Analysis database or Gene Ontology term enrichment. Transcriptional
misregulation in cancer, pathways in cancer and regulation of actin cytoskeleton were identified
(pFDR<0.05) using KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways enrichment.
Using the weighted Kolmogorov–Smirnov test on the entire EWAS discovery results, we noted statistically
significant enrichment for smoking-related CpGs among the lung function-associated CpGs. This
enrichment was also present in the smoking-adjusted EWAS and even in the EWAS restricted to
never-smokers (supplementary table S17).
Association of adult lung function CpG markers with childhood lung function
Using the same scheme of analysis as for the adult replication cohorts, none of the sentinel CpGs showed
associations with FEV1, FVC and FEV1/FVC in the childhood replication cohorts (ALSPAC and IOWBC)
(supplementary table S18). The strongest associations observed in children (p<0.01) were for five CpGs
not known to be smoking-related DNAme markers and one smoking-related CpG (cg00310412
(SEMA7A)).
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FIGURE 2 a, b) Effect of ageing on the associations between DNA methylation (DNAme) and lung function:
quantile–quantile plots of the cross-sectional covariate-adjusted discovery epigenome-wide association study
(EWAS) (Mbase#) on forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) at a) time-point 1 and b)
time-point 2, all participants. Increase in numbers of signals with ageing. For FEV1/FVC, we identified 21
CpGs at time-point 2 compared with three CpGs at time-point 1 to be statistically significant. Meta-analyses
were performed without genomic control (for time-point 1 inflation factor λ=1.15 and for time-point 2 inflation
factor λ=1.14). For analogous figure for cross-sectional associations with FEV1 and FVC, see supplementary
figure S2. c, d) Effect of smoking adjustment on the associations between DNAme and lung function:
quantile–quantile plots of c) the repeat cross-sectional covariate-adjusted discovery EWAS (Mbase#; inflation
factor λ=1.13) and d) additionally smoking adjusted (Msmok¶; inflation factor λ=1.05), all participants. Decrease
in numbers of signals after smoking adjustment. #: base model (Mbase) EWAS was covariate adjusted for age,
age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age
squared, height and squared deviation of height with sex, education (low, medium and high), body mass index,
spirometer type, study centre, and cell composition. ¶: smoking-adjusted model (Msmok): covariates applied
for Mbase and additionally smoking status and pack-years smoked.
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TABLE 3 Combined epigenome-wide association study (EWAS) meta-analyses of cross-sectional associations# of CpG markers with forced expiratory volume in 1 s
(FEV1)/forced vital capacity (FVC) in all participants: base model covariate-adjusted EWAS (Mbase¶)
CpG Chr. Position
(hg19)
Locus b#±SE p-value
meta-analysis
Direction of
effects+
p-value
between-study
heterogeneity
Replicated
p<0.0011§
Previously
reported
smoking CpGƒ
Previously
reported
smoking
pFDR-valueƒ
Previously reported
smoking
association
direction of effectƒ
cg05575921 5 373378 AHRR 0.124±0.008 7.22×10−50 +/+/+/+/+/+/+ 0.023 Yes Yes## 6.10×10−22 (−)
cg03636183 19 17000585 F2RL3 0.201±0.015 4.50×10−43 +/+/+/+/+/+/+ 0.008 Yes Yes## 5.70×10−17 (−)
cg21566642 2 233284661 ALPPL2 0.151±0.011 5.02×10−43 +/+/+/+/+/+/+ 0.043 Yes Yes## 4.50×10−21 (−)
cg01940273 2 233284934 ALPPL2 0.206±0.015 4.09×10−41 +/+/+/+/+/+/+ 0.031 Yes Yes## 9.80×10−30 (−)
cg03329539 2 233283329 ALPPL2 0.257±0.023 5.58×10−30 +/+/+/+/+/+/+ 0.628 Yes Yes 9.70×10−16 (−)
cg21161138 5 399360 AHRR 0.243±0.021 9.72×10−30 +/+/+/+/+/+/+ 0.152 Yes Yes## 7.90×10−13 (−)
cg23771366 11 86510998 PRSS23 0.233±0.022 5.38×10−27 +/+/+/+/+/+/+ 0.286 Yes Yes 1.90×10−14 (−)
cg11660018 11 86510915 PRSS23 0.238±0.023 3.40×10−26 +/+/+/+/+/+/+ 0.318 Yes Yes 4.40×10−21 (−)
cg21611682 11 68138269 LRP5 0.309±0.030 1.26×10−25 +/+/+/+/+/+/+ 0.049 Yes Yes 4.20×10−15 (−)
cg15342087 6 30720209 IER3 0.359±0.036 5.44×10−24 +/+/+/+/+/+/+ 0.169 Yes Yes 3.90×10−14 (−)
cg26703534 5 377358 AHRR 0.266±0.026 7.34×10−24 +/+/+/+/+/+/+ 0.101 Yes Yes 7.20×10−18 (−)
cg25648203 5 395444 AHRR 0.250±0.026 9.84×10−22 +/+/+/+/+/+/+ 0.194 Yes Yes 2.70×10−11 (−)
cg19572487 17 38476024 RARA 0.196±0.021 8.87×10−21 +/+/+/+/+/+/+ 0.018 Yes Yes 1.60×10−16 (−)
cg00310412 15 74724918 SEMA7A 0.261±0.028 4.01×10−20 +/+/+/+/+/+/+ 0.275 Yes Yes 1.20×10−13 (−)
cg24859433 6 30720203 IER3 0.303±0.034 2.05×10−19 +/+/+/+/+/+/+ 0.067 Yes Yes## 2.20×10−9 (−)
cg09935388 1 92947588 GFI1 0.105±0.012 7.05×10−19 +/+/+/+/+/+/+ 0.034 Yes Yes## 7.00×10−14 (−)
cg14753356 6 30720108 IER3 0.189±0.021 9.08×10−19 +/+/+/+/+/+/+ 0.405 Yes Yes 2.30×10−14 (−)
cg04885881 1 11123118 SRM/
EXOSC10
0.168±0.020 5.66×10−18 +/+/+/+/+/+/+ 0.670 Yes Yes 2.70×10−11 (−)
cg25949550 7 145814306 CNTNAP2 0.335±0.039 6.04×10−18 +/+/+/+/+/+/+ 0.013 Yes Yes 9.30×10−21 (−)
cg19859270 3 98251294 GPR15 0.467±0.055 2.80×10−17 +/+/+/+/+/+/+ 0.029 Yes Yes 6.30×10−17 (−)
cg03450842 10 80834947 ZMIZ1 0.265±0.031 2.92×10−17 +/+/+/+/+/+/+ 0.003 Yes Yes 2.40×10−11 (−)
cg03707168 19 49379127 PPP1R15A 0.206±0.025 1.27×10−16 +/+/+/+/+/+/+ 0.668 Yes Yes 3.50×10−7 (−)
cg17087741 2 233283010 ALPPL2 0.161±0.020 4.48×10−16 +/+/+/+/+/+/− <0.001 Yes Yes 6.10×10−7 (−)
cg21140898 1 51442318 CDKN2C 0.120±0.017 4.46×10−13 +/+/+/+/+/+/+ 0.103 Yes Yes 3.70×10−8 (−)
cg01899089 5 369969 AHRR 0.172±0.027 1.47×10−10 +/+/+/+/+/+/+ 0.005 Yes Yes 1.80×10−12 (−)
cg08763102 4 3079751 HTT 0.225±0.039 1.20×10−8 +/+/+/+/+/+/− 0.001 Yes Yes 3.80×10−15 (−)
cg21282907 6 74289980 SLC17A5 0.176±0.031 1.28×10−8 +/+/+/+/+/+/− 0.003 No Yes 1.28×10−2 (−)
cg20853880 2 10184444 KLF11 0.077±0.014 6.05×10−8 +/+/+/+/+/+/+ 0.052 No Yes 3.70×10−7 (−)
cg16391678 16 30485597 ITGAL 0.164±0.031 1.15×10−7 +/+/+/+/+/+/− 0.003 Yes Yes 3.00×10−11 (−)
Chr.: chromosome; hg19: human genome build 19; β: coefficient of association; FDR: false discovery rate. Meta-analyses of cross-sectional associations obtained using data from the
oldest time-point available: time-point 2 of ECRHS, NFBC1966, SAPALDIA and LBC1936; time-point 1 of KORA, LifeLines and NSPHS. For complete results for FEV1/FVC associations,
see supplementary table S3. See supplementary tables S4 and S5 for analogous results for FEV1 and FVC, respectively. #: presentation of CpG markers showing meta-analysis p<5×10−7
in the combined meta-analysis. Note that DNA methylation predictors used were technical bias-adjusted, normalised residuals and thus effect sizes of the association (β) are not directly
comparable to effect sizes reported elsewhere using normalised % methylation as predictor. ¶: base model (Mbase) epigenome-wide association study was covariate adjusted for age, age
squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium and
high), body mass index, spirometer type, study centre as well as cell composition. +: order of cohorts: ECRHS, NFBC1966, SAPALDIA, KORA, LBC1936, LifeLines and NSPHS (FTC was
excluded from this meta-analysis, given the smaller sample size and lower mean age (30.4 years) compared with the other adult cohorts (ECRHS (54.5 years), NFBC1966 (46.3 years),
SAPALDIA (58.8 years) and LBC1936 (76.3 years), and the single available time-point for KORA (60.1 years), LifeLines (46.7 years) and NSPHS (55.1 years)). §: replication was defined for
association if replication p<0.0011 (multiple testing correction, 47 tests for FEV1/FVC). ƒ: smoking CpGs defined on the reported FDR-corrected p<0.05 for association reported with
smoking status and reported direction of effects for association with smoking [2]. ##: smoking CpG previously reported to mediate the effect of smoking on lung function [4].
https://doi.org/10.1183/13993003.00457-2019
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TABLE 4 Combined meta-analyses of the prediction associations# of CpG markers on annual change in forced expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC) in all participants: base model adjustment (Mbase¶)
CpG Chr. Position
(hg19)
Locus Combined meta-analysis
(ECRHS/NFBC1966/SAPALDIA/KORA/LBC1936)
Previously
reported
smoking CpGƒ
Previously
reported
smoking
pFDR-valueƒ
Previously reported
smoking association
direction of effectƒ
b#±SE p-value
meta-analysis
Direction of
effects+
p-value
between-study
heterogeneity
Replicated
p<0.0011§
cg05575921 5 373378 AHRR 0.006±0.001 2.77×10−13 +/+/+/+/+ 0.005 Yes Yes## 6.10×10−22 (−)
cg21566642 2 233284661 ALPPL2 0.006±0.001 3.17×10−11 +/+/+/+/+ 0.235 Yes Yes## 4.50×10−21 (−)
cg01940273 2 233284934 ALPPL2 0.009±0.001 4.93×10−11 +/+/+/+/+ 0.023 Yes Yes## 9.80×10−30 (−)
cg21161138 5 399360 AHRR 0.011±0.002 5.81×10−9 +/+/+/+/+ 0.103 Yes Yes## 7.90×10−13 (−)
cg03636183 19 17000585 F2RL3 0.008±0.001 6.22×10−9 +/+/+/+/+ 0.001 Yes Yes## 5.70×10−17 (−)
cg01377124 2 237172609 ASB18 −0.018±0.003 7.38×10−8 −/−/+/−/+ 0.005 No No NA NA
cg03329539 2 233283329 ALPPL2 0.011±0.002 7.66×10−8 +/+/+/+/+ 0.015 Yes Yes 9.70×10−16 (−)
cg07222133 5 179499488 RNF130 −0.009±0.002 2.45×10−7 ?/−/+/−/+ <0.001 No No NA NA
cg14366110 9 133779382 FIBCD1 0.014±0.003 9.62×10−7 +/+/+/−/− 0.206 No No NA NA
Chr.: chromosome; hg19: human genome build 19; β: coefficient of association; FDR: false discovery rate; NA: not assessed. For complete results for FEV1/FVC and analogous results for
FEV1 and FVC, see supplementary table S8. #: predictive associations of DNA methylation at first time-point (DNAme1) with annual change in lung function during follow-up, defined as
(lung function at second time-point−lung function at first time-point)/time of follow-up (years). Presentation of CpG markers showing meta-analysis p-value<5×10−7 at discovery or
combined meta-analyses level. CpGs shown sorted by statistical significance of combined meta-analysis results. Note that DNAme predictors used were technical bias-adjusted,
normalised residuals and thus effect sizes of the association (β) are not directly comparable to effect sizes reported elsewhere using normalised % methylation as predictor. ¶: base
model (Mbase) epigenome-wide association study was covariate adjusted for age, age squared, height, FEV1/FVC at time-point 1, squared deviation from the mean of height, sex and
interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium and high), body mass index, spirometer type, study centre as well as cell
composition. +: order of cohorts: ECRHS, NFBC1966, SAPALDIA, KORA and LBC1936. §: replication was defined for association if replication p<0.0011 (multiple testing correction, 47 tests
for FEV1/FVC). ƒ: smoking CpGs defined on the reported FDR-corrected p<0.05 for association reported with smoking status and reported direction of effects for association with smoking [2].
##: smoking CpG previously reported to mediate the effect of smoking on lung function [4].
https://doi.org/10.1183/13993003.00457-2019
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Comparison with published DNAme–lung function association reports
Our agnostic results were compared with previously reported lung function-specific [4, 6, 7, 12] or chronic
obstructive pulmonary disease (COPD)-specific [13, 14] DNAme. We retrieved all CpGs reported being
associated with lung function (n=376) for a look-up in the cross-sectional FEV1, FVC and FEV1/FVC
associations at time-point 2. Only 12 out of 376 CpGs showed evidence for association (Bonferroni
correction for 376 tests: p<1.3×10−4) (supplementary table S19). Notably, the most recently reported CpG
markers [4, 6], having also been related to smoking, showed consistent associations with lung function, e.g.
cg05575921 and cg21161138 (AHRR), cg05951221 (near ALPPL2), and cg06126421 (IER3). They were
among our top replicated lung function association signals.
Two-sample Mendelian randomisation investigation
To assess the causality of replicated DNAme–lung function association, we conducted a post hoc
Mendelian randomisation look-up using publicly available databases [15, 16]. Genetic instruments were
identified for 12 replicated CpGs. A two-sample Mendelian randomisation on cross-sectional lung
function could be completed for seven CpGs (supplementary table S20). Results support causal effects for
cg23771366 and cg11660018 (PRSS23), cg21990700 (C1RL), and cg00073460 (ZC3H12D) on FEV1, and
for cg00073460 (ZC3H12D) and cg24086068 (SHROOM3) on FVC.
Integration of DNAme into a smoking index
A recent smoking EWAS followed-up by a mediation analysis identified 10 CpGs as mediators of the
smoking–lung function association [4]. Eight of these mediating CpGs were among our replicated lung
function-associated CpGs (supplementary table S21). In a post hoc mediation analysis in SAPALDIA, we
showed statistically significant average causal mediation on lung function for nine of these mediating CpGs
(FEV1/FVC: table 7; FEV1 and FVC: supplementary table S22).
To assess the combined effect of these smoking exposure-mediating CpGs on lung function, we constructed
a mediation smoking index (Mediation-SI). Its association with lung function by smoking status was tested
in covariate-adjusted regression models in the discovery cohorts and following EWAS models (SAPALDIA,
ECRHS and NFBC1966). Meta-analysed results of Mediation-SI showed strong association with
cross-sectional FEV1/FVC in all participants and ever-smokers (table 8 and figure 4; FEV1 and FVC:
supplementary table S23). Mediation-SI association in all participants was more pronounced for cross-
sectional (β±SE −1.2±0.13; p=2.65×10−20) than for prediction association (β±SE −0.03±0.01; p=0.0072). We
noted comparable associations of Mediation-SI and of pack-years with lung function (figure 5). Both were
inversely associated with level of FEV1/FVC. Adding Mediation-SI or self-reported smoking history
(smoking status and pack-years) to the different Mbase-adjusted statistical models showed a comparable
increase in total adjusted R2. The highest total adjusted R2 was obtained when including both DNAme
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FIGURE 3 a) Manhattan and b) quantile–quantile plots of the covariate-adjusted prediction# epigenome-wide
association study (EWAS) (Mbase¶) on forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC), all
participants. Meta-analysis of the prediction association was performed without genomic control (inflation factor
λ=0.95). For analogous figure for associations with change in FEV1 and FVC, see supplementary figure S4.
#: predictive associations of DNA methylation at first time-point with change in lung function during follow-up.
¶: base model (Mbase) EWAS was covariate adjusted for age, age squared, height, FEV1/FVC at time-point 1,
squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared
deviation of height with sex, education (low, medium and high), body mass index, spirometer type, study centre,
and cell composition.
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TABLE 5 Combined meta-analyses# of cross-sectional associations on forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) in never-smokers only: base
model adjustment (Mbase¶)
CpG Chr. Position
(hg19)
Locus Combined meta-analysis
(ECRHS/NFBC1966/SAPALDIA/KORA/LBC1936/Lifelines/NSPHS)
Previously
reported
smoking CpGƒ
Previously
reported
smoking
pFDR-valueƒ
Previously reported
smoking association
direction of effectƒ
b#±SE p-value
meta-analysis
Direction of
effects+
p-value
between-study
heterogeneity
Replicated
p<0.0011§
cg09884077 15 23086698 NIPA1 −0.308±0.084 0.0003 −/−/−/+/−/−/− 0.001 No No NA NA
cg25758394 1 3623859 TP73 0.213±0.083 0.0107 ?/?/+/−/−/+/− <0.001 No No NA NA
cg18664508 3 169487465 ARPM1 −0.308±0.072 2.02×10−5 +/−/−/−/−/−/− <0.001 No No NA NA
cg19268386 15 23086595 NIPA1 −0.263±0.140 0.0615 ?/?/−/−/−/−/− <0.001 No No NA NA
cg15981995 3 169487311 ARPM1 −0.231±0.073 0.0016 ?/?/−/−/−/−/+ <0.001 No No NA NA
cg05785298 1 204654622 LRRN2 −0.423±0.111 1.41×10−4 −/+/−/+/−/+/− 0.001 No No NA NA
cg20278790 20 57583474 CTSZ 0.319±0.070 5.01×10−6 −/+/+/+/−/−/− <0.001 No No NA NA
cg13562246 8 33368277 C8orf41 0.349±0.074 2.67×10−6 +/+/+/+/+/−/+ 0.206 No No NA NA
Chr.: chromosome; hg19: human genome build 19; β: coefficient of association; FDR: false discovery rate; NA: not assessed. For complete results for FEV1/FVC and for FEV1 and FVC in
never-smokers, see supplementary table S8. #: presentation of CpG markers showing meta-analysis p<5×10−7 at discovery level for cross-sectional association at time-point 2, using
data from time-point 2 of ECRHS, NFBC1966, SAPALDIA and LBC1936 and from time-point 1 of KORA, LifeLines and NSPHS. Note that DNA methylation predictors used were technical
bias-adjusted, normalised residuals and thus effect sizes of the association (β) are not directly comparable to effect sizes reported elsewhere using normalised % methylation as
predictor. ¶: base model (Mbase) epigenome-wide association study was covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction
terms of age, age squared, height and squared deviation of height with sex, education (low, medium and high), body mass index, spirometer type, study centre as well as cell
composition. +: order of cohorts: ECRHS, NFBC1966, SAPALDIA, KORA, LBC1936, LifeLines and NSPHS. §: replication was defined for association if replication p<0.0011 (multiple testing
correction, 47 tests for FEV1/FVC). ƒ: smoking CpGs defined on the reported FDR-corrected p<0.05 for association reported with smoking status and reported direction of effects for
association with smoking [2].
TABLE 6 Combined meta-analyses of the prediction associations# of CpG markers on annual change in forced expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC) in never-smokers only: base model adjustment (Mbase¶)
CpG Chr. Position
(hg19)
Locus Combined meta-analysis
(ECRHS/NFBC1966/SAPALDIA/KORA/LBC1936)
Previously
reported
smoking CpGƒ
Previously
reported
smoking
pFDR-valueƒ
Previously reported
smoking association
direction of effectƒ
b#±SE p-value
meta-analysis
Direction of
effects+
p-value
between-study
heterogeneity
Replicated
p<0.0011§
cg14366110 9 133779382 FIBCD1 0.017±0.003 3.60×10−9 +/+/−/+/+ 0.315 No No NA NA
cg11216682 2 131113867 PTPN18 −0.017±0.003 1.10×10−7 +/−/+/−/− 0.282 No No NA NA
Chr.: chromosome; hg19: human genome build 19; β: coefficient of association; FDR: false discovery rate; NA: not assessed. For complete results for FEV1/FVC and for analogous results
for FEV1 and FVC, see supplementary table S9. #: predictive associations of DNA methylation at first time-point (DNAme1) with annual change in lung function during follow-up, defined
as (lung function at second time-point−lung function at first time-point)/time of follow-up (years). Presentation of CpG markers showing meta-analysis p<5×10−7 at discovery or
replication level. Note that DNAme predictors used were technical bias-adjusted, normalised residuals and thus effect sizes of the association (β) are not directly comparable to effect
sizes reported elsewhere using normalised % methylation as predictor. ¶: base model (Mbase) epigenome-wide association study was covariate adjusted for age, age squared, height,
FEV1/FVC at time-point 1, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low,
medium and high), body mass index, spirometer type, study centre as well as cell composition. +: order of cohorts: ECRHS, NFBC1966, SAPALDIA, KORA and LBC1936. §: replication was
defined for association if replication p<0.0011 (multiple testing correction, 47 tests for FEV1/FVC). ƒ: smoking CpGs defined on the reported FDR-corrected p<0.05 for association reported
with smoking status and reported direction of effects for association with smoking [2].
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TABLE 7 Mediation# analysis on the role of previously reported CpGs in the smoking association with forced expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC): the SAPALDIA cohort
CpG¶ Locus ACME ADE Total effect Proportion
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value
cg01940273 ALPPL2 −0.0079 (−0.0119–−0.0041) <0.0001 −0.0026 (−0.0129–0.0077) 0.604 −0.0106 (−0.0203–−0.0014) 0.026 0.7313 (0.2616–3.4325) 0.026
cg03636183 F2RL3 −0.0080 (−0.0122–−0.0040) <0.0001 −0.0029 (−0.0126–0.0062) 0.556 −0.0108 (−0.0197–−0.0021) 0.018 0.7312 (0.2819–2.9097) 0.018
cg05575921 AHRR −0.0102 (−0.0147–−0.0055) <0.0001 −0.0008 (−0.0109–0.0086) 0.870 −0.0110 (−0.0202–−0.0020) 0.012 0.9213 (0.3818–4.0453) 0.012
cg05951221 ALPPL2 −0.0075 (−0.0122–−0.0030) 0.002 −0.0033 (−0.0131–0.0062) 0.520 −0.0109 (−0.0197–−0.0022) 0.020 0.6836 (0.1942–2.7656) 0.022
cg06126421 IER3 −0.0054 (−0.0093–−0.0017) <0.0001 −0.0049 (−0.0148–0.0049) 0.328 −0.0103 (−0.0194–−0.0012) 0.030 0.5233 (0.1050–2.5558) 0.030
cg09935388 GFI1 −0.0033 (−0.0058–−0.0010) 0.002 −0.0073 (−0.0168–0.0022) 0.122 −0.0105 (−0.0198–−0.0013) 0.034 0.3009 (0.0568–1.4190) 0.036
cg21161138 AHRR −0.0056 (−0.0089–−0.0025) <0.0001 −0.0052 (−0.0146–0.0043) 0.282 −0.0108 (−0.0194–−0.0020) 0.020 0.5127 (0.1647–2.0961) 0.020
cg21566642 ALPPL2 −0.0098 (−0.0145–−0.0057) <0.0001 −0.0014 (−0.0116–0.0089) 0.796 −0.0112 (−0.0209–−0.0011) 0.024 0.8663 (0.3453–4.6567) 0.024
cg22994830 PRKAR1B −0.0002 (−0.0009–0.0003) 0.542 −0.0103 (−0.0201–−0.0010) 0.028 −0.0105 (−0.0202–−0.0013) 0.024 0.0103 (−0.0470–0.1595) 0.550
cg24859433 IER3 −0.0024 (−0.0053–0.0002) 0.068 −0.0082 (−0.0179–0.0013) 0.112 −0.0107 (−0.0201–−0.0014) 0.022 0.2186 (−0.0438–1.2776) 0.090
ACME: average causal mediation effect; ADE: average direct effect. For analogous results for FEV1 and FVC, see supplementary table S22. #: performed using the R package mediation [17].
¶: previously reported candidate CpG for mediation of effect of smoking on lung function [4].
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score and self-reported smoking history. Covariate-adjusted mean Mediation-SI values decreased from
never- to ex- to current smokers and from more distant to more recent smoking exposure, with increase in
pack-years in current smokers and with fewer years since quitting in ex-smokers (figure 6).
TABLE 8 Meta-analyses# of the discovery cohort-specific association of mediation smoking index (Mediation-SI) with forced
expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) (%), cross-sectionally at time-point 2 and longitudinally predicting
the annual change during follow-up, in all study participants, ever and never-smokers: base model adjustment (Mbase¶)
Cross-sectional meta-analysis at time-point 2# Prediction on change in lung function¶
b±SE p-value+ Direction
of effects§
p-value
between-study
heterogeneity
b±SE p-value+ Direction
of effects§
p-value
between-study
heterogeneity
All −0.012±0.0013 1.05×10−20 −/−/− 0.44 −0.0005±0.0001 8.66×10−9 −/−/− 0.006
Ever-smokers −0.014±0.0016 3.28×10−18 −/−/− 0.30 −0.0004±0.0001 4.94×10−4 −/−/− 0.13
Never-smokers −0.0033±0.0041 0.423 −/−/+ 0.62 −0.0007±0.0002 1.73×10−4 +/−/+ 0.003
β: coefficient of association. For analogous results of associations of Mediation-SI with FEV1 and FVC, see supplementary table S23.
#: cohort-specific association results for Mediation-SI were meta-analysed. The 10 CpGs contributing Mediation-SI values are shown in
supplementary table S21. Note that DNA methylation predictors used were technical bias-adjusted, normalised residuals and thus effect sizes
of the association (β) are not directly comparable to effect sizes reported elsewhere using normalised % methylation as predictor. ¶: base
model (Mbase) covariate adjustment: age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age
squared, height and squared deviation of height with sex, education (low, medium and high), body mass index, spirometer type, study centre as
well as cell composition. Prediction models were additionally adjusted for FEV1/FVC at time-point 1. +: p-value of meta-analysis: p<0.008 was
considered statistically significant, Bonferroni correction for six tests per lung function outcome. §: order of cohorts: ECRHS, NFBC1966 and
SAPALDIA.
SAPALDIA
a) b)
c) d)
–0.01 (–0.02– –0.01)
–0.02 (–0.02– –0.01)
–0.02 (–0.02– –0.01)
–0.00 (–0.01–0.01)
–0.01 (–0.02–0.01)
–0.00 (–0.02–0.02)
–0.00 (–0.01–0.00)
0.000 (–0.001–0.001)
–0.001 (–0.001– –0.001)
0.001 (–0.001–0.002)
–0.001 (–0.001– –0.000)
–0.01 (–0.02– –0.01)
–0.03 –0.02 –0.01 0
Mediation-SI estimate (95% CI) Mediation-SI estimate (95% CI)
0.01 0.02 0.03
–0.03 –0.02 –0.01 0
Mediation-SI estimate (95% CI)
0.01 0.02 0.03
–0.002 –0.001 0 0.001 0.002 0.003
Mediation-SI estimate (95% CI)
–0.002 –0.001 0 0.001 0.002 0.003
–0.000 (–0.001–0.000)
–0.000 (–0.001–0.000)
–0.001 (–0.001– –0.000)
–0.000 (–0.001– –0.000)
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p=3.2×10–18,
pheterogeneity=0.30
SAPALDIA
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ECRHS
p=0.423,
pheterogeneity=0.62
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p=0.000173,
pheterogeneity=0.00
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FIGURE 4 Forest plots of cohort-specific results and meta-analyses of the association of the mediation smoking index (Mediation-SI) with forced
expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) and change in FEV1/FVC in a, b) ever-smokers and c, d) never-smokers in the discovery
cohorts: a, c) time-point 2 and b, d) prediction. Associations run applying base model adjustment (Mbase#). #: base model (Mbase) epigenome-wide
association study was covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of
age, age squared, height and squared deviation of height with sex, education (low, medium and high), body mass index, spirometer type, study
centre, and cell composition. Prediction models were additionally adjusted for FEV1/FVC at time-point 1.
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The assessment of a second DNAme smoking score (Lung-Function-Genes-SI), based on smoking-related
CpGs located in 18 GWAS-identified lung function candidate genes (supplementary table S24), showed
less prominent associations with lung function (strongest association observed in ever-smokers for FEV1:
β±SE −0.196±0.053; p=0.0002) (supplementary table S25).
Discussion
The understanding of how environmental exposure and disease are related to site-specific DNAme status
is growing [18, 19]. Our agnostic EWAS on lung function contributes to this body of evidence. Lung
function-associated DNAme markers were strongly enriched for smoking-associated loci. More than 50
known smoking CpGs were consistently, and in several cases causally, associated with lung function and
its change in adults. The current agnostic approach converges with recent results of DNAme–lung
function studies [4, 6, 7] that were a priori focusing on smoking-related loci, and included pyrosequencing
in blood [7] and lung tissue [4] of some of our strongest association signals, including AHRR
hypomethylation at cg05575921 and cg21161138, cg05951221 and cg21566642 (ALPPL2), and cg06126421
(IER3). A methylation index integrating 10 DNAme that reportedly mediate the effect of smoking on lung
function [4] was associated with lung function level and its change in adults.
Smoking is an important risk factor for poor lung function and accelerated decline. Several EWASs
identified a large number of differentially methylated CpG markers to be associated with smoking [2–4]. In
particular, the hypomethylation of cg05575921, a CpG located in the third intron of the aryl hydrocarbon
receptor repressor (AHRR) gene, investigated for lung function and respiratory symptoms [4], stands out as
a robust indicator of smoking status and smoking history [20]. Given the consistency of the associations
observed for cg05575921 and the smoking index containing it in this study, the latter may have potential as
a biomarker of clinical utility in predicting smoking-related morbidity and mortality [20, 21]. The positive
direction of effects observed in identified DNAme–lung function association is in accordance with the
–1 0 1 2 3 4 5
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0.75
a) b)
Mediation-SI
FE
V1
/F
VC
FE
V1
/F
VC
0 50 100 150
0.65
0.70
0.75
Smoking history pack-years
FIGURE 5 Distribution and association# of a) mediation smoking index (Mediation-SI)¶ and b) self-reported
smoking history (pack-years) with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) with 95%
confidence intervals (shaded). Box plots of a) Mediation-SI (median (range) 0.3 (−1.7–5.2)) and b) pack-years
(median (range) 2.0 (0–145.9)) in all participants of SAPALDIA are shown at the top of each panel. Red dotted
lines indicate box plot interquartile range (IQR) borders. Whiskers indicate 1.5 IQR of the lower and upper
quartile; outliers are indicated. For analogous figures for associations of Mediation-SI with FEV1 and FVC, see
supplementary figures S6 and S7, respectively. #: associations were adjusted for the base model (Mbase): age,
age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age
squared, height and squared deviation of height with sex, education (low, medium and high), body mass index,
spirometer type, study centre, and cell composition. ¶: Mediation-SI can be constructed for all participants
irrespective of their smoking status. The Mbase-adjusted model explained 17.5% of the variance in the
outcome. The Mbase-adjusted model additionally adjusted for the Mediation-SI explained 19.6% of the FEV1/
FVC variance (total adjusted R2=0.196) of which 2.8% of the variance was specifically explained by the
Mediation-SI variable. This was comparable to the variance explained by the Mbase-adjusted model
additionally adjusted for pack-years and smoking status corresponding to the Msmok model (R2=0.198, and
with 1.6% of the variance specifically explained by the pack-years variable). Model including both smoking
adjustments (Msmok and additionally Mediation-SI) explained 20.1% of the FEV1/FVC variance.
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reported hypomethylation of smoking-related DNAme sites. The identified lung function-associated
CpGs in this study have been previously reported to be associated with smoking-related molecular
phenotypes [22], with increased risk of noncommunicable disease, including cancer [20, 23], and with
epigenetically defined accelerated ageing [24].
Whether most smoking-related DNAme markers are only markers of exposure or indirectly associated with
lung function [7] or whether some inform on causal disease pathways cannot be answered conclusively by
the current study. First, DNAme may just be a more precise measure of smoking exposure than
self-reporting, as AHRR DNAme was previously shown to correlate with genetic smoking dependency [20].
Second, DNAme identified by previous smoking EWASs [2, 4] may not exclusively have picked up
methylation effects of smoking, but methylation related to phenotypes also affected by smoking. In this
case, the observed DNAme–lung function associations may result from comorbidity between lung function
and other smoking-related phenotypes. However, some of the results are consistent with a causal disease
pathway. First, Mendelian randomisation results support causal effects from some DNAme. Unfortunately,
no genetic instrument was available for the top ranked AHRR signal. Second, our report confirms nine
CpGs, including cg05575921 (AHRR), previously shown to mediate the effect of smoking of lung function [4].
The observation that many smoking DNAme–lung function associations withstood smoking adjustment is
consistent with the mediating role of DNAme between smoking behaviour (more distant predictor) and
lung function. Third, smoking was also observed to influence methylation in lung tissue at several lung
function CpGs, including at cg05575921 in AHRR, and these methylation levels correlated with AHRR
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FIGURE 6 Distribution of adjusted mediation smoking index (Mediation-SI) in SAPALDIA at time-point 2. a)
Smoking status: adjusted for age, sex and education. Never-smokers (n=395), ex-smokers (n=356) and
current smokers (n=211). b) Years since quitting: adjusted for age, sex, education, pack-years and cigarettes
per day. Ex-smokers (n=356). c) Pack-years: adjusted for age, sex, education and cigarettes per day. Current
smokers (n=211). d) Cigarettes per day: adjusted for age, sex, education and pack-years. Current smokers
(n=211). Data are presented as median with interquartile range (IQR) (boxes) and 1.5 IQR of the lower and
upper quartile (whiskers); outliers are indicated.
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gene expression [25] and expression of other genes [4]. Hypotheses for a mediating and causal role of
smoking-related DNAme include altered AHRR DNAme inducing altered phase 2 enzyme activity and
toxicant metabolism, and altered inflammatory pathways in the lung [7]. Other inhalants impacting on the
same pathways could in part explain the observed enrichment for smoking DNAme among
never-smokers. Methylation of AHRR cg05575921 was previously associated with lung function and
chronic bronchitis in never-smokers [7]. Maternal smoking, passive smoking and environmental exposures
other than cigarette smoking (e.g. air pollution) are known to modify DNAme patterns across the genome
[26–32]. Maternal smoking during pregnancy has been shown to alter the offspring’s DNA markers in a
number of genes known to contain smoking-related CpGs [27, 28] and some of these epigenetic patterns,
including in AHRR, persist to adulthood [29].
From our findings in two well-characterised childhood birth cohorts, there was no evidence for shared
common epigenetic mechanisms underlying lung function in adults and children. The comparison was
driven by results from the lung function EWAS in adults, given sample size limitations in the available
birth cohorts. Lung function in childhood versus adulthood is expected to be influenced in part by
different biological processes. The nonreplication of the mostly smoking-related lung function DNAme
signals might reflect the nonsmoking status of the children and adolescents. Our findings in SAPALDIA
point to a dose–response effect of smoking history and intensity on the smoking index. Effects of maternal
exposure in utero, passive smoking or other inhalants on smoking DNAme are likely smaller than the
effects of active smoking [30]. Our EWAS findings generally showed an age-related increase in number
and strength of DNAme–lung function associations in adults, despite covariate adjustment for age, as also
observed by others [6]. This result is consistent with the observed dose–response effect of smoking and
possibly other inhalants on DNAme. However, the inherent interdependency of lung function decline,
cumulative smoking exposure and DNAme with ageing prohibits attributing associations to single factors.
A systematic review of peripheral DNAme associated with lung function in population-based cohorts
pointed to the lack of consistent evidence [5]. Epigenome-wide DNAme profiling studies of lung tissue
suggested DNAme in genes such as NOS1AP, TNFAIP2 and CHRM1 to be associated with COPD [13, 14].
An EWAS meta-analysis, adjusted for smoking status and pack-years, identified differential DNAme
related to COPD and lung function in Koreans. Five loci (CTU2, USP36, ZNF516, KLK10 and CPT1B)
were associated with at least two respiratory traits [12]. Evidence of associations in the current EWAS was
only observed for 12 out of 376 CpGs associated with lung function phenotypes in these previous studies.
This inconsistency may be due to differences in population ancestry, disease status, exposure status,
tissue-specific methylation or covariate adjustment. Furthermore, limited sample size and false discovery
findings could contribute to nonreplication, as could the absence of post-bronchodilation lung function in
the current EWAS. However, our results confirm the associations of two recently published population-
based reports [4, 6] investigating smoking, DNAme and lung function. Both reports and our results reveal
the same smoking CpGs as prominent signals.
The strength of this EWAS investigation is the robust and extensive study design with availability of repeat
measures of DNAme and spirometry data in the same cohort participants, as well as its population-based
design. The utilisation of a multilevel analysis scheme, including cross-sectional and longitudinal EWAS
analyses at two time-points in the same participants, and EWAS with and without smoking adjustment in
all participants and in never-smokers, allowed for a better understanding of lung function DNAme being
affected by ageing and smoking. The lung function-associated smoking index derived is building on robust
evidence that DNAme in blood is correlated with DNAme and gene expression in lung tissue [4, 23, 33],
and that it is a valid biomarker for capturing the effect of smoking on DNAme in the lung [7, 20].
There are several limitations to this study. Limitations in sample size may explain the inability to find
association signals in never-smokers and therefore signals common to lung function in childhood and
adulthood. The estimation of decline in lung function from only two spirometry time-points is likely to
misclassify decline. Additionally, not all replication cohorts had data available for more than one
time-point. Pre-bronchodilation lung function is less robust than post-bronchodilator values and may
increase variability of the findings. The meta-analysed EWAS results of the cross-sectional analyses showed
evidence of inflation (inflation factor λ>1.1) indicating insufficient genomic control; however, adjusting for
genomic inflation did not alter our main results. The relevance of the smoking index derived from CpGs
in or close to lung function GWAS genes can be questioned given evidence on the complex
trans-regulation of gene expression [34].
In conclusion, our agnostic investigation shows that DNAme at CpGs related to smoking behaviour are the
predominant signals associated cross-sectionally and prospectively with lung function in adults. The
findings stimulate further research into the involvement of smoking-related CpGs in lung function-
relevant mechanisms and potentially their role as exposure markers beyond active smoking. From our
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EWAS results it has become clear that larger samples are required to confidently identify CpGs involved in
lung function and its age-related decline in persons who never smoked.
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